<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">36529289</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1083-351X</ISSN><JournalIssue CitedMedium="Internet"><Volume>299</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>A minimal construct of nuclear-import receptor Karyopherin-&#x3b2;2 defines the regions critical for chaperone and disaggregation activity.</ArticleTitle><Pagination><StartPage>102806</StartPage><MedlinePgn>102806</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102806</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbc.2022.102806</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0021-9258(22)01249-2</ELocationID><Abstract><AbstractText>Karyopherin-&#x3b2;2 (Kap&#x3b2;2) is a nuclear-import receptor that recognizes proline-tyrosine nuclear localization signals of diverse cytoplasmic cargo for transport to the nucleus. Kap&#x3b2;2 cargo includes several disease-linked RNA-binding proteins with prion-like domains, such as FUS, TAF15, EWSR1, hnRNPA1, and hnRNPA2. These RNA-binding proteins with prion-like domains are linked via pathology and genetics to debilitating degenerative disorders, including amyotrophic lateral sclerosis, frontotemporal dementia, and multisystem proteinopathy. Remarkably, Kap&#x3b2;2 prevents and reverses aberrant phase transitions of these cargoes, which is cytoprotective. However, the molecular determinants of Kap&#x3b2;2 that enable these activities remain poorly understood, particularly from the standpoint of nuclear-import receptor architecture. Kap&#x3b2;2 is a super-helical protein comprised of 20 HEAT repeats. Here, we design truncated variants of Kap&#x3b2;2 and assess their ability to antagonize FUS aggregation and toxicity in yeast and FUS condensation at the pure protein level and in human cells. We find that HEAT repeats 8 to 20 of Kap&#x3b2;2 recapitulate all salient features of Kap&#x3b2;2 activity. By contrast, Kap&#x3b2;2 truncations lacking even a single cargo-binding HEAT repeat display reduced activity. Thus, we define a minimal Kap&#x3b2;2 construct for delivery in adeno-associated viruses as a potential therapeutic for amyotrophic lateral sclerosis/frontotemporal dementia, multisystem proteinopathy, and related disorders.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fare</LastName><ForeName>Charlotte M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhine</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland, USA; Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myong</LastName><ForeName>Sua</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program in Cell, Molecular, Developmental Biology, and Biophysics, Johns Hopkins University, Baltimore, Maryland, USA; Department of Biophysics, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shorter</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Biochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA. Electronic address: jshorter@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 GM099836</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AG065854</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D028961">beta Karyopherins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010446">Peptide Fragments</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011328">Prions</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C108121">TNPO1 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028961" MajorTopicYN="Y">beta Karyopherins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000229" MajorTopicYN="N">Dependovirus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066298" MajorTopicYN="N">In Vitro Techniques</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="Y">Molecular Chaperones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010446" MajorTopicYN="Y">Peptide Fragments</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011328" MajorTopicYN="Y">Prions</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057165" MajorTopicYN="N">Proteostasis Deficiencies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="Y">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012441" MajorTopicYN="N">Saccharomyces cerevisiae</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FUS</Keyword><Keyword MajorTopicYN="N">chaperone</Keyword><Keyword MajorTopicYN="N">disaggregase</Keyword><Keyword MajorTopicYN="N">nuclear-import receptor</Keyword><Keyword MajorTopicYN="N">nucleocytoplasmic transport</Keyword><Keyword MajorTopicYN="N">phase separation</Keyword></KeywordList><CoiStatement>Conflict of interest C. M. F., K. R., A. L., and S. M. have no interests to declare. J. S. is a consultant for Dewpoint Therapeutics, ADRx, and Neumora. J.S. is a shareholder and advisor for Confluence Therapeutics.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>18</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36529289</ArticleId><ArticleId IdType="pmc">PMC9860449</ArticleId><ArticleId IdType="doi">10.1016/j.jbc.2022.102806</ArticleId><ArticleId IdType="pii">S0021-9258(22)01249-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lee B.J., Cansizoglu A.E., Suel K.E., Louis T.H., Zhang Z., Chook Y.M. Rules for nuclear localization sequence recognition by Karyopherin beta 2. Cell. 2006;126:543&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3442361</ArticleId><ArticleId IdType="pubmed">16901787</ArticleId></ArticleIdList></Reference><Reference><Citation>Soniat M., Chook Y.M. Nuclear localization signals for four distinct Karyopherin-beta nuclear import systems. Biochem. J. 2015;468:353&#x2013;362.</Citation><ArticleIdList><ArticleId IdType="pubmed">26173234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing C.E., Fung H.Y.J., Chook Y.M. Karyopherin-mediated nucleocytoplasmic transport. Nat. Rev. Mol. Cell Biol. 2022;23:307&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101760</ArticleId><ArticleId IdType="pubmed">35058649</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Farmer A., Chook Y.M. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr. Opin. Struct. Biol. 2010;20:782&#x2013;790.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2994982</ArticleId><ArticleId IdType="pubmed">20951026</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorlich D., Pante N., Kutay U., Aebi U., Bischoff F.R. Identification of different roles for RanGDP and RanGTP in nuclear protein import. EMBO J. 1996;15:5584&#x2013;5594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC452303</ArticleId><ArticleId IdType="pubmed">8896452</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Fare C.M., Shorter J. Therapeutic dissolution of aberrant phases by nuclear-import receptors. Trends Cell Biol. 2019;29:308&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750949</ArticleId><ArticleId IdType="pubmed">30660504</ArticleId></ArticleIdList></Reference><Reference><Citation>Chook Y.M., Blobel G. Structure of the nuclear transport complex Karyopherin-beta2-Ran x GppNHp. Nature. 1999;399:230&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">10353245</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakielny S., Dreyfuss G. Import and export of the nuclear protein import receptor transportin by a mechanism independent of GTP hydrolysis. Curr. Biol. 1998;8:89&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">9427645</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakielny S., Siomi M.C., Siomi H., Michael W.M., Pollard V., Dreyfuss G. Transportin: nuclear transport receptor of a novel nuclear protein import pathway. Exp. Cell Res. 1996;229:261&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">8986607</ArticleId></ArticleIdList></Reference><Reference><Citation>Siomi M.C., Eder P.S., Kataoka N., Wan L., Liu Q., Dreyfuss G. Transportin-mediated nuclear import of heterogeneous nuclear RNP proteins. J.&#xa0;Cell Biol. 1997;138:1181&#x2013;1192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2132560</ArticleId><ArticleId IdType="pubmed">9298975</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard V.W., Michael W.M., Nakielny S., Siomi M.C., Wang F., Dreyfuss G. A&#xa0;novel receptor-mediated nuclear protein import pathway. Cell. 1996;86:985&#x2013;994.</Citation><ArticleIdList><ArticleId IdType="pubmed">8808633</ArticleId></ArticleIdList></Reference><Reference><Citation>Soniat M., Chook Y.M. Karyopherin-&#x3b2;2 recognition of a PY-NLS variant that lacks the proline-tyrosine motif. Structure. 2016;24:1802&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5053885</ArticleId><ArticleId IdType="pubmed">27618664</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xfc;el K.E., Gu H., Chook Y.M. Modular organization and combinatorial energetics of proline-tyrosine nuclear localization signals. PLoS Biol. 2008;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2408616</ArticleId><ArticleId IdType="pubmed">18532879</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z.C., Chook Y.M. Structural and energetic basis of ALS-causing mutations in the atypical proline-tyrosine nuclear localization signal of the fused in sarcoma protein (FUS) Proc. Natl. Acad. Sci. U. S. A. 2012;109:12017&#x2013;12021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409756</ArticleId><ArticleId IdType="pubmed">22778397</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifaci N., Moroianu J., Radu A., Blobel G. Karyopherin beta2 mediates nuclear import of a mRNA binding protein. Proc. Natl. Acad. Sci. U. S. A. 1997;94:5055&#x2013;5060.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC24630</ArticleId><ArticleId IdType="pubmed">9144189</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo L., Kim H.J., Wang H., Monaghan J., Freyermuth F., Sung J.C., et al. Nuclear-import receptors reverse aberrant phase transitions of RNA-binding proteins with prion-like domains. Cell. 2018;173:677&#x2013;692.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5911940</ArticleId><ArticleId IdType="pubmed">29677512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofweber M., Hutten S., Bourgeois B., Spreitzer E., Niedner-Boblenz A., Schifferer M., et al. Phase separation of FUS is suppressed by its nuclear import receptor and arginine methylation. Cell. 2018;173:706&#x2013;719.e13.</Citation><ArticleIdList><ArticleId IdType="pubmed">29677514</ArticleId></ArticleIdList></Reference><Reference><Citation>Qamar S., Wang G., Randle S.J., Ruggeri F.S., Varela J.A., Lin J.Q., et al. FUS phase separation is modulated by a molecular chaperone and methylation of arginine cation-pi interactions. Cell. 2018;173:720&#x2013;734.e15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5927716</ArticleId><ArticleId IdType="pubmed">29677515</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshizawa T., Ali R., Jiou J., Fung H.Y.J., Burke K.A., Kim S.J., et al. Nuclear import receptor inhibits phase separation of FUS through binding to multiple sites. Cell. 2018;173:693&#x2013;705.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234985</ArticleId><ArticleId IdType="pubmed">29677513</ArticleId></ArticleIdList></Reference><Reference><Citation>Niaki A.G., Sarkar J., Cai X., Rhine K., Vidaurre V., Guy B., et al. Loss of dynamic RNA interaction and aberrant phase separation induced by two distinct types of ALS/FTD-linked FUS mutations. Mol. Cell. 2020;77:82&#x2013;94.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6943187</ArticleId><ArticleId IdType="pubmed">31630970</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhine K., Dasovich M., Yoniles J., Badiee M., Skanchy S., Ganser L.R., et al. Poly(ADP-ribose) drives condensation of FUS via a transient interaction. Mol. Cell. 2022;82:969&#x2013;985.e11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9330637</ArticleId><ArticleId IdType="pubmed">35182479</ArticleId></ArticleIdList></Reference><Reference><Citation>Baade I., Hutten S., Sternburg E.L., Porschke M., Hofweber M., Dormann D., et al. The RNA-binding protein FUS is chaperoned and imported into the nucleus by a network of import receptors. J.&#xa0;Biol. Chem. 2021;296:100659.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131929</ArticleId><ArticleId IdType="pubmed">33857479</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez A., Mannen T., Cagatay T., Fujiwara A., Matsumura H., Niesman A.B., et al. Mechanism of Karyopherin-beta2 binding and nuclear import of ALS variants FUS(P525L) and FUS(R495X) Sci. Rep. 2021;11:3754.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7881136</ArticleId><ArticleId IdType="pubmed">33580145</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhine K., Makurath M.A., Liu J., Skanchy S., Lopez C., Catalan K.F., et al. ALS/FTLD-linked mutations in FUS glycine residues cause accelerated gelation and reduced interactions with wild-type FUS. Mol. Cell. 2020;80:666&#x2013;681.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7688085</ArticleId><ArticleId IdType="pubmed">33159856</ArticleId></ArticleIdList></Reference><Reference><Citation>Darling A.L., Shorter J. Combating deleterious phase transitions in neurodegenerative disease. Biochim. Biophys. Acta Mol. Cell Res. 2021;1868:118984.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7965345</ArticleId><ArticleId IdType="pubmed">33549703</ArticleId></ArticleIdList></Reference><Reference><Citation>Fare C.M., Shorter J. (Dis)Solving the problem of aberrant protein states. Dis. Model. Mech. 2021;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8126477</ArticleId><ArticleId IdType="pubmed">33942880</ArticleId></ArticleIdList></Reference><Reference><Citation>Odeh H.M., Fare C.M., Shorter J. Nuclear-import receptors counter deleterious phase transitions in neurodegenerative disease. J.&#xa0;Mol. Biol. 2022;434:167220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8748273</ArticleId><ArticleId IdType="pubmed">34464655</ArticleId></ArticleIdList></Reference><Reference><Citation>Portz B., Lee B.L., Shorter J. FUS and TDP-43 phases in health and disease. Trends Biochem. Sci. 2021;46:550&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8195841</ArticleId><ArticleId IdType="pubmed">33446423</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridell R.A., Truant R., Thorne L., Benson R.E., Cullen B.R. Nuclear import of hnRNP A1 is mediated by a novel cellular cofactor related to karyopherin-beta. J.&#xa0;Cell Sci. 1997;110:1325&#x2013;1331.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202393</ArticleId></ArticleIdList></Reference><Reference><Citation>King O.D., Gitler A.D., Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res. 2012;1462:61&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372647</ArticleId><ArticleId IdType="pubmed">22445064</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.R., King O.D., Shorter J., Gitler A.D. Stress granules as crucibles of ALS pathogenesis. J.&#xa0;Cell Biol. 2013;201:361&#x2013;372.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639398</ArticleId><ArticleId IdType="pubmed">23629963</ArticleId></ArticleIdList></Reference><Reference><Citation>Cushman M., Johnson B.S., King O.D., Gitler A.D., Shorter J. Prion-like disorders: blurring the divide between transmissibility and infectivity. J.&#xa0;Cell Sci. 2010;123:1191&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2848109</ArticleId><ArticleId IdType="pubmed">20356930</ArticleId></ArticleIdList></Reference><Reference><Citation>Gitler A.D., Shorter J. RNA-binding proteins with prion-like domains in ALS and FTLD-U. Prion. 2011;5:179&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3226045</ArticleId><ArticleId IdType="pubmed">21847013</ArticleId></ArticleIdList></Reference><Reference><Citation>March Z.M., King O.D., Shorter J. Prion-like domains as epigenetic regulators, scaffolds for subcellular organization, and drivers of neurodegenerative disease. Brain Res. 2016;1647:9&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003744</ArticleId><ArticleId IdType="pubmed">26996412</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison A.F., Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem. J. 2017;474:1417&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapeli K., Martinez F.J., Yeo G.W. Genetic mutations in RNA-binding proteins and their roles in ALS. Hum. Genet. 2017;136:1193&#x2013;1214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5602095</ArticleId><ArticleId IdType="pubmed">28762175</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J., Hart M.P., Erion R., King O.D., Diaz Z., Nakaya T., et al. Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral sclerosis. Hum. Mol. Genet. 2012;21:2899&#x2013;2911.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3373238</ArticleId><ArticleId IdType="pubmed">22454397</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J., Hart M.P., Shorter J., DeJesus-Hernandez M., Erion R., Oristano R., et al. A&#xa0;yeast functional screen predicts new candidate ALS disease genes. Proc. Natl. Acad. Sci. U. S. A. 2011;108:20881&#x2013;20890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3248518</ArticleId><ArticleId IdType="pubmed">22065782</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Kim N.C., Wang Y.D., Scarborough E.A., Moore J., Diaz Z., et al. Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013;495:467&#x2013;473.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3756911</ArticleId><ArticleId IdType="pubmed">23455423</ArticleId></ArticleIdList></Reference><Reference><Citation>Beijer D., Kim H.J., Guo L., O'Donovan K., Mademan I., Deconinck T., et al. Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight. 2021;6</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8410042</ArticleId><ArticleId IdType="pubmed">34291734</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Mohassel P., Donkervoort S., Guo L., O'Donovan K., Coughlin M., et al. Heterozygous frameshift variants in HNRNPA2B1 cause early-onset oculopharyngeal muscular dystrophy. Nat. Commun. 2022;13:2306.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050844</ArticleId><ArticleId IdType="pubmed">35484142</ArticleId></ArticleIdList></Reference><Reference><Citation>Couthouis J., Raphael A.R., Daneshjou R., Gitler A.D. Targeted exon capture and sequencing in sporadic amyotrophic lateral sclerosis. PLoS Genet. 2014;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4191946</ArticleId><ArticleId IdType="pubmed">25299611</ArticleId></ArticleIdList></Reference><Reference><Citation>Blokhuis A.M., Groen E.J., Koppers M., van den Berg L.H., Pasterkamp R.J. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol. 2013;125:777&#x2013;794.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3661910</ArticleId><ArticleId IdType="pubmed">23673820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito D., Hatano M., Suzuki N. RNA binding proteins and the pathological cascade in ALS/FTD neurodegeneration. Sci. Transl. Med. 2017;9</Citation><ArticleIdList><ArticleId IdType="pubmed">29118263</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie I.R., Rademakers R., Neumann M. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia. Lancet Neurol. 2010;9:995&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">20864052</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Rademakers R., Roeber S., Baker M., Kretzschmar H.A., Mackenzie I.R. A&#xa0;new subtype of frontotemporal lobar degeneration with FUS pathology. Brain. 2009;132:2922&#x2013;2931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2768659</ArticleId><ArticleId IdType="pubmed">19674978</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyzack G.E., Luisier R., Taha D.M., Neeves J., Modic M., Mitchell J.S., et al. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis. Brain. 2019;142:2572&#x2013;2580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6735815</ArticleId><ArticleId IdType="pubmed">31368485</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Scotter E.L., Nishimura A.L., Troakes C., Mitchell J.C., Kathe C., et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 2013;22:2676&#x2013;2688.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208.</Citation><ArticleIdList><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoell J.I., Larsson E., Runge S., Nusbaum J.D., Duggimpudi S., Farazi T.A., et al. RNA targets of wild-type and mutant FET family proteins. Nat. Struct. Mol. Biol. 2011;18:1428&#x2013;1431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3230689</ArticleId><ArticleId IdType="pubmed">22081015</ArticleId></ArticleIdList></Reference><Reference><Citation>Humphrey J., Birsa N., Milioto C., McLaughlin M., Ule A.M., Robaldo D., et al. FUS ALS-causative mutations impair FUS autoregulation and splicing factor networks through intron retention. Nucleic Acids Res. 2020;48:6889&#x2013;6905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7337901</ArticleId><ArticleId IdType="pubmed">32479602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamelgarn M., Chen J., Kuang L., Jin H., Kasarskis E.J., Zhu H. ALS mutations of FUS suppress protein translation and disrupt the regulation of nonsense-mediated decay. Proc. Natl. Acad. Sci. U. S. A. 2018;115:E11904&#x2013;E11913.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6304956</ArticleId><ArticleId IdType="pubmed">30455313</ArticleId></ArticleIdList></Reference><Reference><Citation>Korobeynikov V.A., Lyashchenko A.K., Blanco-Redondo B., Jafar-Nejad P., Shneider N.A. Antisense oligonucleotide silencing of FUS expression as a therapeutic approach in amyotrophic lateral sclerosis. Nat. Med. 2022;28:104&#x2013;116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8799464</ArticleId><ArticleId IdType="pubmed">35075293</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami T., Qamar S., Lin J.Q., Schierle G.S., Rees E., Miyashita A., et al. ALS/FTD mutation-induced phase transition of FUS liquid droplets and reversible hydrogels into irreversible hydrogels impairs RNP granule function. Neuron. 2015;88:678&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4660210</ArticleId><ArticleId IdType="pubmed">26526393</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai Y.L., Coady T.H., Lu L., Zheng D., Alland I., Tian B., et al. ALS/FTD-associated protein FUS induces mitochondrial dysfunction by preferentially sequestering respiratory chain complex mRNAs. Genes Dev. 2020;34:785&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7263147</ArticleId><ArticleId IdType="pubmed">32381627</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdile V., De Paola E., Paronetto M.P. Aberrant phase transitions: side effects and novel therapeutic strategies in human disease. Front. Genet. 2019;10:173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6440380</ArticleId><ArticleId IdType="pubmed">30967892</ArticleId></ArticleIdList></Reference><Reference><Citation>Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. EMBO J. 2008;27:336&#x2013;349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2234348</ArticleId><ArticleId IdType="pubmed">18216876</ArticleId></ArticleIdList></Reference><Reference><Citation>Coady T.H., Manley J.L. ALS mutations in TLS/FUS disrupt target gene expression. Genes Dev. 2015;29:1696&#x2013;1706.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561479</ArticleId><ArticleId IdType="pubmed">26251528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes E., Shorter J. The molecular language of membraneless organelles. J.&#xa0;Biol. Chem. 2019;294:7115&#x2013;7127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6509512</ArticleId><ArticleId IdType="pubmed">30045872</ArticleId></ArticleIdList></Reference><Reference><Citation>Fare C.M., Villani A., Drake L.E., Shorter J. Higher-order organization of biomolecular condensates. Open Biol. 2021;11:210137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8205532</ArticleId><ArticleId IdType="pubmed">34129784</ArticleId></ArticleIdList></Reference><Reference><Citation>Levone B.R., Lenzken S.C., Antonaci M., Maiser A., Rapp A., Conte F., et al. FUS-dependent liquid-liquid phase separation is important for DNA repair initiation. J.&#xa0;Cell Biol. 2021;220</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7953258</ArticleId><ArticleId IdType="pubmed">33704371</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F., Lu S., Yu H., Chen C., Melamed Z., Guo L., et al. Cytoplasmic TDP-43 de-mixing independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102:339&#x2013;357.e7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Molliex A., Temirov J., Lee J., Coughlin M., Kanagaraj A.P., Kim H.J., et al. Phase separation by low complexity domains promotes stress granule assembly and drives pathological fibrillization. Cell. 2015;163:123&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5149108</ArticleId><ArticleId IdType="pubmed">26406374</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallegger M., Chakrabarti A.M., Lee F.C.Y., Lee B.L., Amalietti A.G., Odeh H.M., et al. TDP-43 condensation properties specify its RNA-binding and regulatory repertoire. Cell. 2021;184:4680&#x2013;4696.e22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445024</ArticleId><ArticleId IdType="pubmed">34380047</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato M., Han T.W., Xie S., Shi K., Du X., Wu L.C., et al. Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell. 2012;149:753&#x2013;767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6347373</ArticleId><ArticleId IdType="pubmed">22579281</ArticleId></ArticleIdList></Reference><Reference><Citation>Buchan J.R., Parker R. Eukaryotic stress granules: the ins and outs of translation. Mol. Cell. 2009;36:932&#x2013;941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2813218</ArticleId><ArticleId IdType="pubmed">20064460</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahboubi H., Stochaj U. Cytoplasmic stress granules: dynamic modulators of cell signaling and disease. Biochim. Biophys. Acta Mol. Basis Dis. 2017;1863:884&#x2013;895.</Citation><ArticleIdList><ArticleId IdType="pubmed">28095315</ArticleId></ArticleIdList></Reference><Reference><Citation>Protter D.S.W., Parker R. Principles and properties of stress granules. Trends Cell Biol. 2016;26:668&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993645</ArticleId><ArticleId IdType="pubmed">27289443</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B., Ivanov P. Stress granules and neurodegeneration. Nat. Rev. Neurosci. 2019;20:649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel A., Lee H.O., Jawerth L., Maharana S., Jahnel M., Hein M.Y., et al. A&#xa0;liquid-to-solid phase transition of the ALS protein FUS accelerated by disease mutation. Cell. 2015;162:1066&#x2013;1077.</Citation><ArticleIdList><ArticleId IdType="pubmed">26317470</ArticleId></ArticleIdList></Reference><Reference><Citation>Reineke L.C., Neilson J.R. Differences between acute and chronic stress granules, and how these differences may impact function in human disease. Biochem. Pharmacol. 2019;162:123&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6421087</ArticleId><ArticleId IdType="pubmed">30326201</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P., Fan B., Yang P., Temirov J., Messing J., Kim H.J., et al. Chronic optogenetic induction of stress granules is cytotoxic and reveals the evolution of ALS-FTD pathology. Elife. 2019;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426440</ArticleId><ArticleId IdType="pubmed">30893049</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann J.R., Gleixner A.M., Mauna J.C., Gomes E., DeChellis-Marks M.R., Needham P.G., et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102:321&#x2013;338.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutten S., Usluer S., Bourgeois B., Simonetti F., Odeh H.M., Fare C.M., et al. Nuclear import receptors directly bind to arginine-rich dipeptide repeat proteins and suppress their pathological interactions. Cell Rep. 2020;33:108538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7814465</ArticleId><ArticleId IdType="pubmed">33357437</ArticleId></ArticleIdList></Reference><Reference><Citation>Jovicic A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015;18:1226&#x2013;1229.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4552077</ArticleId><ArticleId IdType="pubmed">26308983</ArticleId></ArticleIdList></Reference><Reference><Citation>Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.H., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature. 2015;525:129&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4631399</ArticleId><ArticleId IdType="pubmed">26308899</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes L.R., Duan L., Bowen K., Kalab P., Rothstein J.D. C9orf72 arginine-rich dipeptide repeat proteins disrupt karyopherin-mediated nuclear import. Elife. 2020;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7051184</ArticleId><ArticleId IdType="pubmed">32119645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicardi M., Kankate V., Sriramoji S., Krishnamurthy K., Markandaiah S., Verdone B., et al. Kap&#x3b2;2 is a modifier of the C9orf72-linked glycine-arginine dipeptide neurotoxicity. bioRxiv. 2022 doi: 10.1101/2022.09.30.510384. [preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.09.30.510384</ArticleId><ArticleId IdType="pmc">PMC8979946</ArticleId><ArticleId IdType="pubmed">35379876</ArticleId></ArticleIdList></Reference><Reference><Citation>Conte A., Lattante S., Zollino M., Marangi G., Luigetti M., Del Grande A., et al. P525L FUS mutation is consistently associated with a severe form of juvenile amyotrophic lateral sclerosis. Neuromuscul. Disord. 2012;22:73&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">21907581</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P., Danel V., Lacour A., Beltran S., Andres C., Couratier P., et al. A&#xa0;novel mutation of the C-terminal amino acid of FUS (Y526C) strengthens FUS gene as the most frequent genetic factor in aggressive juvenile ALS. Amyotroph. Lateral Scler. Frontotemporal Degener. 2017;18:298&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">28054830</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu C., Zhang J., Gao F., Yang L., Jia M., Zhu H., et al. FUS-NLS/transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS One. 2012;7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3466232</ArticleId><ArticleId IdType="pubmed">23056579</ArticleId></ArticleIdList></Reference><Reference><Citation>Chook Y.M., Blobel G. Karyopherins and nuclear import. Curr. Opin. Struct. Biol. 2001;11:703&#x2013;715.</Citation><ArticleIdList><ArticleId IdType="pubmed">11751052</ArticleId></ArticleIdList></Reference><Reference><Citation>Cansizoglu A.E., Lee B.J., Zhang Z.C., Fontoura B.M., Chook Y.M. Structure-based design of a pathway-specific nuclear import inhibitor. Nat. Struct. Mol. Biol. 2007;14:452&#x2013;454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437620</ArticleId><ArticleId IdType="pubmed">17435768</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura S.H., Hirano T. HEAT repeats &#x2013; versatile arrays of amphiphilic helices working in crowded environments? J.&#xa0;Cell Sci. 2016;129:3963&#x2013;3970.</Citation><ArticleIdList><ArticleId IdType="pubmed">27802131</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukuhara N., Fernandez E., Ebert J., Conti E., Svergun D. Conformational variability of nucleo-cytoplasmic transport factors. J.&#xa0;Biol. Chem. 2004;279:2176&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">14561738</ArticleId></ArticleIdList></Reference><Reference><Citation>Cansizoglu A.E., Chook Y.M. Conformational heterogeneity of Karyopherin beta2 is segmental. Structure. 2007;15:1431&#x2013;1441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437625</ArticleId><ArticleId IdType="pubmed">17997969</ArticleId></ArticleIdList></Reference><Reference><Citation>Iijima M., Suzuki M., Tanabe A., Nishimura A., Yamada M. Two motifs essential for nuclear import of the hnRNP A1 nucleocytoplasmic shuttling sequence M9 core. FEBS Lett. 2006;580:1365&#x2013;1370.</Citation><ArticleIdList><ArticleId IdType="pubmed">16455081</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J., Southworth D.R. Spiraling in control: structures and mechanisms of the Hsp104 disaggregase. Cold Spring Harb. Perspect. Biol. 2019;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6671941</ArticleId><ArticleId IdType="pubmed">30745294</ArticleId></ArticleIdList></Reference><Reference><Citation>Erives A.J., Fassler J.S. Metabolic and chaperone gene loss marks the origin of animals: evidence for Hsp104 and Hsp78 chaperones sharing mitochondrial enzymes as clients. PLoS One. 2015;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4339202</ArticleId><ArticleId IdType="pubmed">25710177</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter J. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals. 2008;16:63&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">18097161</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeny E.A., Shorter J. Mechanistic and structural insights into the prion-disaggregase activity of Hsp104. J.&#xa0;Mol. Biol. 2016;428:1870&#x2013;1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860052</ArticleId><ArticleId IdType="pubmed">26608812</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju S., Tardiff D.F., Han H., Divya K., Zhong Q., Maquat L.E., et al. A&#xa0;yeast model of FUS/TLS-dependent cytotoxicity. PLoS Biol. 2011;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082520</ArticleId><ArticleId IdType="pubmed">21541368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Z., Diaz Z., Fang X., Hart M.P., Chesi A., Shorter J., et al. Molecular determinants and genetic modifiers of aggregation and toxicity for the ALS disease protein FUS/TLS. PLoS Biol. 2011;9</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3082519</ArticleId><ArticleId IdType="pubmed">21541367</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel M.E., DeSantis M.E., Martinez B.A., Castellano L.M., Stewart R.M., Caldwell K.A., et al. Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell. 2014;156:170&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3909490</ArticleId><ArticleId IdType="pubmed">24439375</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatelli M., Moncada A., Conte A., Lattante S., Marangi G., Luigetti M., et al. Mutations in the 3' untranslated region of FUS causing FUS overexpression are associated with amyotrophic lateral sclerosis. Hum. Mol. Genet. 2013;22:4748&#x2013;4755.</Citation><ArticleIdList><ArticleId IdType="pubmed">23847048</ArticleId></ArticleIdList></Reference><Reference><Citation>Dini Modigliani S., Morlando M., Errichelli L., Sabatelli M., Bozzoni I. An ALS-associated mutation in the FUS 3'-UTR disrupts a microRNA-FUS regulatory circuitry. Nat. Commun. 2014;5:4335.</Citation><ArticleIdList><ArticleId IdType="pubmed">25004804</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel M.E., Shorter J. Potentiated Hsp104 variants suppress toxicity of diverse neurodegenerative disease-linked proteins. Dis. Model. Mech. 2014;7:1175&#x2013;1184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4174528</ArticleId><ArticleId IdType="pubmed">25062688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackrel M.E., Yee K., Tariq A., Chen A.I., Shorter J. Disparate mutations confer therapeutic gain of Hsp104 function. ACS Chem. Biol. 2015;10:2672&#x2013;2679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684741</ArticleId><ArticleId IdType="pubmed">26441009</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A., Lin J., Jackrel M.E., Hesketh C.D., Carman P.J., Mack K.L., et al. Mining disaggregase sequence space to safely counter TDP-43, FUS, and alpha-synuclein proteotoxicity. Cell Rep. 2019;28:2080&#x2013;2095.e6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6750954</ArticleId><ArticleId IdType="pubmed">31433984</ArticleId></ArticleIdList></Reference><Reference><Citation>Yasuda K., Clatterbuck-Soper S.F., Jackrel M.E., Shorter J., Mili S. FUS inclusions disrupt RNA localization by sequestering kinesin-1 and inhibiting microtubule detyrosination. J.&#xa0;Cell Biol. 2017;216:1015&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5379945</ArticleId><ArticleId IdType="pubmed">28298410</ArticleId></ArticleIdList></Reference><Reference><Citation>Daigle J.G., Lanson N.A., Jr., Smith R.B., Casci I., Maltare A., Monaghan J., et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum. Mol. Genet. 2013;22:1193&#x2013;1205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3578413</ArticleId><ArticleId IdType="pubmed">23257289</ArticleId></ArticleIdList></Reference><Reference><Citation>Barmada S.J., Ju S., Arjun A., Batarse A., Archbold H.C., Peisach D., et al. Amelioration of toxicity in neuronal models of amyotrophic lateral sclerosis by hUPF1. Proc. Natl. Acad. Sci. U. S. A. 2015;112:7821&#x2013;7826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4485101</ArticleId><ArticleId IdType="pubmed">26056265</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq A., Lin J., Noll M.M., Torrente M.P., Mack K.L., Murillo O.H., et al. Potentiating Hsp104 activity via phosphomimetic mutations in the middle domain. FEMS Yeast Res. 2018;18</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454557</ArticleId><ArticleId IdType="pubmed">29788207</ArticleId></ArticleIdList></Reference><Reference><Citation>Dian C., Bernaudat F., Langer K., Oliva M.F., Fornerod M., Schoehn G., et al. Structure of a truncation mutant of the nuclear export factor CRM1 provides insights into the auto-inhibitory role of its C-terminal helix. Structure. 2013;21:1338&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pubmed">23850454</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsytlonok M., Craig P.O., Sivertsson E., Serquera D., Perrett S., Best R.B., et al. Complex energy landscape of a giant repeat protein. Structure. 2013;21:1954&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4256716</ArticleId><ArticleId IdType="pubmed">24120762</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson E., Shorter J., Guo L. Karyopherin-beta2 inhibits and reverses aggregation and liquid-liquid phase separation of the ALS/FTD-associated protein FUS. Bio Protoc. 2020;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7842781</ArticleId><ArticleId IdType="pubmed">33659387</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Gal J., Chen J., Zhu H. Self-assembled FUS binds active chromatin and regulates gene transcription. Proc. Natl. Acad. Sci. U. S. A. 2014;111:17809&#x2013;17814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273402</ArticleId><ArticleId IdType="pubmed">25453086</ArticleId></ArticleIdList></Reference><Reference><Citation>Reber S., Jutzi D., Lindsay H., Devoy A., Mechtersheimer J., Levone B.R., et al. The phase separation-dependent FUS interactome reveals nuclear and cytoplasmic function of liquid-liquid phase separation. Nucleic Acids Res. 2021;49:7713&#x2013;7731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287939</ArticleId><ArticleId IdType="pubmed">34233002</ArticleId></ArticleIdList></Reference><Reference><Citation>Mallet P.L., Bachand F. A&#xa0;proline-tyrosine nuclear localization signal (PY-NLS) is required for the nuclear import of fission yeast PAB2, but not of human PABPN1. Traffic. 2013;14:282&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">23279110</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeny E.A., Jackrel M.E., Go M.S., Sochor M.A., Razzo B.M., DeSantis M.E., et al. The Hsp104 N-terminal domain enables disaggregase plasticity and potentiation. Mol. Cell. 2015;57:836&#x2013;849.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623595</ArticleId><ArticleId IdType="pubmed">25620563</ArticleId></ArticleIdList></Reference><Reference><Citation>Bayliss R., Littlewood T., Stewart M. Structural basis for the interaction between FxFG nucleoporin repeats and importin-beta in nuclear trafficking. Cell. 2000;102:99&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">10929717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bednenko J., Cingolani G., Gerace L. Importin beta contains a COOH-terminal nucleoporin binding region important for nuclear transport. J.&#xa0;Cell Biol. 2003;162:391&#x2013;401.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2172684</ArticleId><ArticleId IdType="pubmed">12885761</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi N.C., Adam S.A. Functional domains in nuclear import factor p97 for binding the nuclear localization sequence receptor and the nuclear pore. Mol. Biol. Cell. 1997;8:945&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC305705</ArticleId><ArticleId IdType="pubmed">9201707</ArticleId></ArticleIdList></Reference><Reference><Citation>Kutay U., Izaurralde E., Bischoff F.R., Mattaj I.W., Gorlich D. Dominant-negative mutants of importin-beta block multiple pathways of import and export through the nuclear pore complex. EMBO J. 1997;16:1153&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1169714</ArticleId><ArticleId IdType="pubmed">9135132</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas L., Askjaer P., Seydoux G. Multiple mechanisms prevent ectopic condensation of FG nucleoporins in the cytoplasm. bioRxiv. 2022 doi: 10.1101/2022.08.22.504855. [preprint]</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.22.504855</ArticleId></ArticleIdList></Reference><Reference><Citation>Chook Y.M., Jung A., Rosen M.K., Blobel G. Uncoupling Kapbeta2 substrate dissociation and ran binding. Biochemistry. 2002;41:6955&#x2013;6966.</Citation><ArticleIdList><ArticleId IdType="pubmed">12033928</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Madl T., Valori C.F., Bentmann E., Tahirovic S., Abou-Ajram C., et al. Arginine methylation next to the PY-NLS modulates transportin binding and nuclear import of FUS. EMBO J. 2012;31:4258&#x2013;4275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3501225</ArticleId><ArticleId IdType="pubmed">22968170</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D., Rodde R., Edbauer D., Bentmann E., Fischer I., Hruscha A., et al. ALS-associated fused in sarcoma (FUS) mutations disrupt transportin-mediated nuclear import. EMBO J. 2010;29:2841&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924641</ArticleId><ArticleId IdType="pubmed">20606625</ArticleId></ArticleIdList></Reference><Reference><Citation>Sproviero W., La Bella V., Mazzei R., Valentino P., Rodolico C., Simone I.L., et al. FUS mutations in sporadic amyotrophic lateral sclerosis: clinical and genetic analysis. Neurobiol. Aging. 2012;33:837 e831&#x2013;e835.</Citation><ArticleIdList><ArticleId IdType="pubmed">22055719</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q., Shu S., Wang R.R., Liu F., Cui B., Guo X.N., et al. Whole-exome sequencing identifies a missense mutation in hnRNPA1 in a family with flail arm ALS. Neurology. 2016;87:1763&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pubmed">27694260</ArticleId></ArticleIdList></Reference><Reference><Citation>Naruse H., Ishiura H., Mitsui J., Date H., Takahashi Y., Matsukawa T., et al. Molecular epidemiological study of familial amyotrophic lateral sclerosis in Japanese population by whole-exome sequencing and identification of novel HNRNPA1 mutation. Neurobiol. Aging. 2018;61:255.e9&#x2013;255.e16.</Citation><ArticleIdList><ArticleId IdType="pubmed">29033165</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey J.L., Guo L. Liquid-liquid phase separation of TDP-43 and FUS in physiology and pathology of neurodegenerative diseases. Front. Mol. Biosci. 2022;9:826719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847598</ArticleId><ArticleId IdType="pubmed">35187086</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuzmin D.A., Shutova M.V., Johnston N.R., Smith O.P., Fedorin V.V., Kukushkin Y.S., et al. The clinical landscape for AAV gene therapies. Nat. Rev. Drug Discov. 2021;20:173&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">33495615</ArticleId></ArticleIdList></Reference><Reference><Citation>Au H.K.E., Isalan M., Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings. Front. Med. 2021;8:809118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8864161</ArticleId><ArticleId IdType="pubmed">35223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell J.R., Al-Zaidy S.A., Rodino-Klapac L.R., Goodspeed K., Gray S.J., Kay C.N., et al. Current clinical applications of in&#xa0;vivo gene therapy with AAVs. Mol. Ther. 2021;29:464&#x2013;488.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7854298</ArticleId><ArticleId IdType="pubmed">33309881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z., Yang H., Colosi P. Effect of genome size on AAV vector packaging. Mol. Ther. 2010;18:80&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2839202</ArticleId><ArticleId IdType="pubmed">19904234</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrone L., Marchi P.M., Azzouz M. Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders. Expert Opin. Biol. Ther. 2022;22:1163&#x2013;1176.</Citation><ArticleIdList><ArticleId IdType="pubmed">34904932</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.J., Taylor J.P. Lost in transportation: nucleocytoplasmic transport defects in ALS and other neurodegenerative diseases. Neuron. 2017;96:285&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5678982</ArticleId><ArticleId IdType="pubmed">29024655</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore S., Rabichow B.E., Sattler R. The hitchhiker's guide to nucleocytoplasmic trafficking in neurodegeneration. Neurochem. Res. 2020;45:1306&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">32086712</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallini C., Khalil B., Smith C.L., Rossoll W. Traffic jam at the nuclear pore: all roads lead to nucleocytoplasmic transport defects in ALS/FTD. Neurobiol. Dis. 2020;140:104835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7253339</ArticleId><ArticleId IdType="pubmed">32179176</ArticleId></ArticleIdList></Reference><Reference><Citation>Shubina-Oleinik O., Nist-Lund C., French C., Rockowitz S., Shearer A.E., Holt J.R. Dual-vector gene therapy restores cochlear amplification and auditory sensitivity in a mouse model of DFNB16 hearing loss. Sci. Adv. 2021;7:eabi7629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8673757</ArticleId><ArticleId IdType="pubmed">34910522</ArticleId></ArticleIdList></Reference><Reference><Citation>Gietz R.D., Schiestl R.H. High-efficiency yeast transformation using the LiAc/SS carrier DNA/PEG method. Nat. Protoc. 2007;2:31&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">17401334</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J., Arganda-Carreras I., Frise E., Kaynig V., Longair M., Pietzsch T., et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Schirmer E.C., Homann O.R., Kowal A.S., Lindquist S. Dominant gain-of-function mutations in Hsp104p reveal crucial roles for the middle region. Mol. Biol. Cell. 2004;15:2061&#x2013;2072.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC404004</ArticleId><ArticleId IdType="pubmed">14978213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cormack B.P., Valdivia R.H., Falkow S. FACS-optimized mutants of the green fluorescent protein (GFP) Gene. 1996;173:33&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pubmed">8707053</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider C.A., Rasband W.S., Eliceiri K.W. NIH image to ImageJ: 25 years of image analysis. Nat. Methods. 2012;9:671&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5554542</ArticleId><ArticleId IdType="pubmed">22930834</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>